Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Pidnarulex in High grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements: NCT07069699 Clinical Landscape Report 2026
28 September 2026
NCT07069699 clinical landscape for High grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements: endpoints, sponsor, phase, geography, readouts, a…
9 min read
Carboplatin in Recurrent Triple-Negative Breast Carcinoma: CTRI/2025/07/091252 Clinical Landscape Report 2026
28 September 2026
CTRI/2025/07/091252 clinical landscape for Recurrent Triple-Negative Breast Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and deve…
9 min read
Orelabrutinib in Diffuse Large B-Cell Lymphoma: NCT07078500 Clinical Landscape Report 2026
28 September 2026
NCT07078500 clinical landscape for Diffuse Large B-Cell Lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Sargramostim in PD-L1 negative Triple Negative Breast Cancer: NCT07078604 Clinical Landscape Report 2026
28 September 2026
NCT07078604 clinical landscape for PD-L1 negative Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and developmen…
9 min read
Sintilimab in Follicular Lymphoma: NCT07077512 Clinical Landscape Report 2026
28 September 2026
NCT07077512 clinical landscape for Follicular Lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
SONALA-001 in Glioblastoma Multiforme: NCT07076472 Clinical Landscape Report 2026
28 September 2026
NCT07076472 clinical landscape for Glioblastoma Multiforme: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
SC-101 in Hormone receptor positive breast cancer: NCT07080619 Clinical Landscape Report 2026
28 September 2026
NCT07080619 clinical landscape for Hormone receptor positive breast cancer: endpoints, sponsor, phase, geography, readouts, asset context and development whi…
9 min read
Zeprumetostat in High grade B-cell lymphoma: NCT07082803 Clinical Landscape Report 2026
28 September 2026
NCT07082803 clinical landscape for High grade B-cell lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
[18F]DCFPyL in Renal Cell Carcinoma: NCT07084909 Clinical Landscape Report 2026
28 September 2026
NCT07084909 clinical landscape for Renal Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
IBR854 in Advanced Renal Cell Carcinoma: NCT07087158 Clinical Landscape Report 2026
28 September 2026
NCT07087158 clinical landscape for Advanced Renal Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Recombinant oncolytic virus M1(Guangzhou Vitron) in Glioblastoma: NCT07093814 Clinical Landscape Report 2026
28 September 2026
NCT07093814 clinical landscape for Glioblastoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Etoposide in High grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements: NCT07097363 Clinical Landscape Report 2026
28 September 2026
NCT07097363 clinical landscape for High grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements: endpoints, sponsor, phase, geography, readouts, a…